Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps Agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments ...

Core Viewpoint - Johnson & Johnson MedTech is undergoing a systematic restructuring of its business portfolio in response to growth pressures and structural adjustments in the medical device industry, focusing on three core segments: cardiovascular, surgical, and vision [2][3]. Business Composition - The company plans to narrow its focus from four business segments to three core areas: cardiovascular, surgical, and vision, reallocating resources and innovation towards these areas [3][5]. - The decision to spin off the orthopedic business, DePuy Synthes, is seen as a growth-oriented choice to optimize the business structure and create space for higher quality growth [3][5]. Cardiovascular Segment - The cardiovascular segment is highlighted as the most impactful and potentially lucrative area, with significant growth driven by strategic acquisitions, including the $16 billion purchase of Abiomed [6][7]. - Currently, approximately 50% of the company's products are in high-growth markets, with annual revenue for the cardiovascular segment reaching $7.7 billion, a 21.4% increase from 2023 [6]. Surgical Segment - The surgical business has faced challenges, with a 1.9% decline in annual revenue, influenced by market competition and a contraction in the Chinese market [8][10]. - Future growth is expected to hinge on the success of the surgical robot project, Ottava, which aims to enhance surgical workflows and space utilization [8][10]. Vision Segment - The vision segment serves around 40 million people annually and has seen a cumulative sales growth of 31% over the past five years, second only to cardiovascular [13]. - The segment's revenue is projected to grow by 1.5% in 2024, reaching $5.1 billion, with a focus on differentiated product offerings to enhance growth certainty [13]. Regional and Investment Strategy - The company acknowledges challenges in the Chinese market, previously a growth engine, and is reallocating resources to the U.S. and other markets [14]. - Continuous investment in R&D is emphasized, with a planned $3.7 billion investment in 2024, a 19% increase from the previous year, alongside strategic investments in emerging technologies [14][15]. Orthopedic Spin-off - The spin-off of DePuy Synthes is a significant structural decision aimed at improving overall growth rates and profit levels, allowing both the parent company and the new entity to focus on their respective markets [16]. Conclusion - The next phase for Johnson & Johnson MedTech is centered around focus, integration, and execution, aiming to concentrate resources on high-potential areas while enhancing long-term competitiveness through innovation and decentralized management [17].

智通财经编辑 | 谢欣 2025年年末的罗永浩科技创新分享大会上，罗永浩迟到40多分钟才出现在讲台。随后他在微博上提及自 己患有ADHD（注意缺陷与多动障碍）一事。该疾病由此再引发关注。ADHD对一些家长来说更不陌 生，治疗该病的哌甲酯类药物一度被俗称为"聪明药"，甚至在未严格确诊的群体中也受到追捧。 当下该领域亦有新进展。 1月6日，爱科百发宣布，其复方氯丝右哌甲酯胶囊（商品名：爱智达）获国家药监局批准，适用于治疗 6岁及6岁以上ADHD患者。这也是爱科百发首个进入商业化阶段的产品。 据爱科百发招股书，该复方制剂包含30%速释右哌甲酯（d-MPH）和70%丝右哌甲酯（SDX，右哌甲酯 前药）。通过胃肠道吸收后，丝右哌甲酯转化为右哌甲酯。这一设计可以全天逐步释放右哌甲酯，通过 右哌甲酯快速控制症状，并通过丝右哌甲酯延长治疗时间，实现稳定的全天ADHD症状控制。 该复方制剂由Commave研发，2021年3月在美获批（商品名：AZSTARYS）。同年12月，爱科百发以总 价1.055亿美元获得该药的大中华区权益。 源：视觉中国 智通财经记者 | 陈杨 | 药品名 | 初始剂量(mg)及加量方法 | | 用药频率 ...

Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs On December 30, Barclays raised its price target on Johnson & Johnson (NYSE:JNJ) to $217 from $197 and kept an Equal Weight rating on the shares. The firm reviewed sales and prescription data through the final week of December and sees room for upside to Q4 consensus estimates. The strength is coming mainly from Darzalex, Tremfy ...

Key Takeaways J&J said nipocalimab met the primary endpoint in the phase IIb JASMINE study in SLE.The study also hit key secondary and exploratory endpoints, including signals for steroid sparing.Nipocalimab is approved under the brand name Imaavy for treating generalized myasthenia gravis.Johnson & Johnson (JNJ) announced that the phase IIb JASMINE study, which evaluated its pipeline candidate, nipocalimab, for treating adult patients with systemic lupus erythematosus (SLE), has met the primary endpoint.Th ...

Key Takeaways J&J's diversified pharma and MedTech model supports steadier growth across cycles.JNJ's 2025 gains were driven by Innovative Medicine growth and improving MedTech performance.AZN's oncology-led growth is offset by patent expirations, Part D pressure and China-related headwinds.Johnson & Johnson (JNJ) and AstraZeneca (AZN) rank among the world’s largest pharmaceutical companies, each with a broad and diversified healthcare portfolio. Both companies have a strong presence in oncology. Other than ...

Retail investors have been increasingly following the trading activity of members of Congress, with some disclosures sparking interest in unfollowed stocks or companies that could benefit from potential government contracts. A member of Congress may not have caused red flags with his latest purchase of blue-chip, dividend-paying stock, but investors may want to take note.Congressman Buys Dow Jones Industrial Average StocksCongressman Lloyd Doggett (D-Texas) recently disclosed several new stock purchases, as ...

Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called systemic lupus erythematosus, reached the main goal of a mid-stage trial. Based on topline data, the New Brunswick, New Jersey-based pharma giant said that its ...

Core Insights - The JASMINE study achieved its primary endpoint and key secondary and exploratory endpoints, indicating the potential of nipocalimab for steroid sparing in systemic lupus erythematosus (SLE) [2][4] - Johnson & Johnson plans to initiate a Phase 3 program for nipocalimab based on the positive topline results from the Phase 2b study [2][5] Company Overview - Johnson & Johnson is focused on innovative medicine and aims to address complex diseases through advanced healthcare solutions [11] - The company has a strong commitment to developing treatments that are safe, tolerable, and capable of reducing disease activity while preserving immune function [5] Industry Context - SLE is a chronic autoimmune disease affecting approximately 3 to 5 million people globally, with around 450,000 cases in the U.S. [3][9] - The disease significantly impacts health-related quality of life, with symptoms including severe fatigue, joint pain, and rashes [9] - There is a critical need for new immunoselective therapies due to complications associated with long-term steroid use in SLE patients [5]

Core Insights - Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency (EMA) for an indication extension of TECVAYLI® (teclistamab) in combination with DARZALEX® (daratumumab SC) for treating adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy [1][2] Group 1: Clinical Study and Results - The application is supported by data from the Phase 3 MajesTEC-3 study, which showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) compared to standard treatment [1][2] - The MajesTEC-3 study enrolled 587 patients and demonstrated an 83.4% reduction in the risk of disease progression or death compared to standard regimens at nearly three years follow-up (hazard ratio [HR], 0.17; 95% confidence interval [CI], 0.12-0.23; P<0.0001) [2][4] - More than 90% of patients who remained progression-free at six months continued to be progression-free at three years [2] Group 2: Treatment Efficacy and Safety - Teclistamab and daratumumab SC work in a complementary manner by targeting both BCMA and CD38, enhancing immune-mediated responses earlier in treatment [2] - The combination regimen showed similar rates of Grade 3/4 treatment-emergent adverse events (TEAE) compared to standard care (95.1% vs. 96.6%) [2] - The most common Grade 3/4 events were cytopenia and infection, with infections observed in 96.5% of patients receiving teclistamab and daratumumab SC [2] Group 3: Regulatory and Market Position - The FDA has granted Breakthrough Therapy Designation for the teclistamab and daratumumab SC combination, expediting its development and regulatory review [2] - Johnson & Johnson aims to redefine treatment possibilities in multiple myeloma by using the right medicines early and combining them for optimal outcomes [3] Group 4: Background on Multiple Myeloma - Multiple myeloma is an incurable blood cancer affecting plasma cells, with over 35,000 new diagnoses in the EU in 2022 [8] - Patients experience frequent relapses, and remissions become progressively shorter with each line of therapy [8]